| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 280, Issue 45, 37377-37382, November 11, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peptides*
From the Litwin-Zucker Research Center for the Study of Alzheimer's Disease and Memory Disorders, North Shore-Long Island Jewish Institute for Medical Research, Manhasset, New York 11030
Received for publication, July 27, 2005 , and in revised form, September 12, 2005.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
(A) peptides produced from different cell lines. Resveratrol does not inhibit A production, because it has no effect on the A-producing enzymes - and 
-secretases, but promotes instead intracellular degradation of A via a mechanism that involves the proteasome. Indeed, the resveratrol-induced decrease of A could be prevented by several selective proteasome inhibitors and by siRNA-directed silencing of the proteasome subunit 5. These findings demonstrate a proteasome-dependent anti-amyloidogenic activity of resveratrol and suggest that this natural compound has a therapeutic potential in Alzheimer's disease. |
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
in the pathogenesis of the disease (1). A is a core component of the senile plaque, a classical lesion found in the neocortex and hippocampus of AD brains, and excessive production of the highly insoluble 42-amino acid-long A42 peptide is almost invariably observed in the presence of mutations in the three genes linked to early onset autosomal dominant familial forms of AD (2).
In the amyloidogenic pathway, the amyloid- precursor protein (APP) is cleaved by the aspartic protease -secretase/BACE1 to yield the membrane-anchored C-terminal fragments C99 and C89. C99 is then endoproteolyzed by the -secretase proteolytic complex to produce various A peptides. The major cleavage takes place after Val-40 producing A40. In an alternative nonamyloidogenic pathway, APP is endoproteolyzed within the A region by 
-secretase to generate the C-terminal fragment C83 and the soluble N-terminal fragment secreted APP. Finally, a -secretase-mediated 
-cleavage of APP allows the intracellular release of the transcriptionally active APP intracellular domain (AID (3) or AICD) (4–6).
Epidemiological studies have shown that moderate wine intake reduces the risk of developing AD (7–10). Resveratrol, a polyphenol that occurs in abundance in grapes and red wine, is suspected to afford antioxidant and neuroprotective properties and therefore to contribute to the beneficial effect of wine consumption on the neurodegenerative process (11–13). Here we report that resveratrol has a potent anti-amyloidogenic activity by reducing the levels of A produced from different cell lines expressing wild type or Swedish mutant APP695. We show that resveratrol acts by promoting the intracellular degradation of A by a mechanism that implicates the proteasome.
|
EXPERIMENTAL PROCEDURES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
-(1–17) (6E10) and anti-A-(17–24) (4G8, pure and biotinylated) antibodies were from Signet. Anti-APP-(66–81) (22C11) antibody was from Chemicon, and anti-APP C-terminal domain (R1) antibody was provided by Dr. P. D. Mehta, Institute for Basic Research in Developmental Disabilities, Staten Island, NY. Polyclonal antibodies specific for A40 (FCA3340) or A42 (FCA3542) (14) were obtained from Dr. F. Checler, IPMC-Centre National de la Recherche Scientifique, Valbonne, France. Anti-N-cadherin (C32) and anti--catenin antibodies were from BD Transduction Laboratories. Anti-20 S proteasome subunit 5 antibody was from ABR Affinity BioReagents, and the polyclonal antibody directed against the subunits 5, 7, 1, 5, 5i, and 7 of the 20 S proteasome was from Biomol. Anti--tubulin antibody was from Santa Cruz Biotechnology.
Cell Lines, Transfections, and Drug Treatments—HEK293 cells stably transfected with human APP695 were provided by Dr. L. D'Adamio, Albert Einstein College of Medicine, Bronx, NY. N2a cells were stably transfected with wild type or Swedish mutant human APP695 cDNAs (obtained from Dr. N. K. Robakis, Mount Sinai School of Medicine, New York, NY). APP695-HEK293 transfectants were grown in Dulbecco's modified Eagle's medium plus 10% fetal bovine serum, penicillin and streptomycin, and 5 µg/ml puromycin. APP695-N2a cells were maintained in 1:1 Dulbecco's modified Eagle's medium/Opti-MEM supplemented with 5% fetal bovine serum, penicillin and streptomycin, and 0.2 mg/ml G418. For drug treatments, cells were treated at confluence for the indicated concentrations and incubation times. Medium was then changed, and treatments were continued for another 2 h to allow A secretion. For siRNA-directed silencing, 200 pmol of purified siRNA directed against the proteasome subunit 5 (SMARTpool, Dharmacon) were transfected with 10 µl of Lipofectamine 2000 (Invitrogen) in APP695-HEK293 cells plated in 35-mm dishes. At 48 h post-transfection, cells were incubated in the absence or presence of 40 µM resveratrol for another 24 h. Cells and conditioned medium were harvested and analyzed by Western blotting (WB) and by proteasome activity assays as described below.
Western Blotting—Cells were washed with phosphate-buffered saline and solubilized in ice-cold HEPES buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 1x Complete protease inhibitor mixture, Roche Applied Science) containing 1% SDS. Ten micrograms of extracts were analyzed by SDS-PAGE. For total sA WB, conditioned medium was subjected to 0.2-µm filtration. Twenty microliters of medium were then electrophoresed on 16.5% Tris-Tricine gels and transferred onto 0.2-µm nitrocellulose membranes. Membranes were microwaved for 5 min in phosphate-buffered saline, blocked in 5% fat-free milk in TBS, and incubated with 6E10 (1:1000 in Pierce SuperBlock) overnight at 4 °C. A standard ECL detection procedure was then used.
A Immunoprecipitations (IPs)—Cells were solubilized in ice-cold RIPA buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1x Complete). Five hundred micrograms of cell extracts (for total intracellular A IP) or 1 ml of the corresponding conditioned medium diluted in 4x RIPA buffer (for sA40 and sA42 IPs) were precleared with protein A- or protein G-Sepharose (Amersham Biosciences) for 2 h at 4°C. Supernatants were then incubated overnight at 4 °C with 3 µl of antibodies 4G8 (total intracellular A IP), FCA3340 (sA40 IP), or FCA3542 (sA42 IP). Supernatants were then treated for 2 h at 4 °C with protein A-Sepharose (polyclonal antibodies) or with protein G-Sepharose (monoclonal antibodies). IPs were washed with ice-cold RIPA buffer and analyzed by WB using the 6E10 antibody as described above.
A Enzyme-linked Immunosorbent Assay (ELISA)— 6E10 (capture antibody) was coated at 2 µg/ml in coating buffer (2.27 g/liter K2HPO4, 3.48 g/liter KH2PO4, pH 7.2, 8 g/liter NaCl, 0.372 g/liter EDTA, 0.1 g/liter NaN3) into 96-well immunoassay plates for 24 h at 4 °C. The plates were washed with 0.05% Tween 20 in TBS (TTBS) and blocked with Pierce TBS starting block buffer for 1 h at room temperature. The samples (conditioned medium or A1–40 standards) and biotinylated 4G8 (reporter antibody, at 0.5 µg/ml in 20% Pierce SuperBlock) were then added to the plates and incubated at room temperature for 2 h. Following washing with TTBS, streptavidin-horseradish peroxidase (Southern Biotech, at 0.25 µg/ml in 20% SuperBlock) was added to the wells for 1 h at room temperature. The fluorogenic substrate Amplex Ultra Red (Molecular Probes) was added to the plates and incubated for 15 min. Reaction products were quantified using a Tecan Genios Pro plate reader at 535 nm excitation and 590 nm emission.
Enzymatic Activity Assays—For neprilysin (NEP) activity assays, intact cells were incubated at 37 °C for 2 h in Opti-MEM containing 50 µM Suc-AAF-AMC in the absence or presence of 20 µM thiorphan. Cells were then homogenized, and protein concentrations were determined using a Bradford assay (Bio-Rad). Chymotrypsin-like activity of the endogenous proteasome was determined by solubilizing the cells in activity assay buffer (25 mM HEPES, pH 7.5, 0.5 mM EDTA, 0.05% Nonidet P-40, and 0.001% SDS). Cell extracts (40 µg) were incubated at 37°C for 2 h in 100 µl of activity assay buffer containing 50 µM Suc-LLVY-AMC in the absence or presence of 10 µM of ALLN. For purified proteasome activity assays, 12.5 µg/ml purified human 20 S proteasome were incubated at 37 °C for 2 h in 100 µl of activity assay buffer containing 50 µM Suc-LLVY-AMC. Release of AMC was measured by fluorescence spectrophotometry using wavelengths of 340 nm excitation and 535 nm emission (Tecan Genios Pro). Enzymatic activities were expressed as nmol AMC/min/mg protein.
|
|
|
-Secretase Assays—In vitro assays were performed as described previously (15). Briefly, cells were resuspended in 0.5 ml/35-mm dish of hypotonic buffer (10 mM MOPS, pH 7.0, 10 mM KCl) and homogenized on ice. A postnuclear supernatant was prepared by centrifugation at 1000 x g for 15 min at 4 °C. Crude membranes were isolated from the postnuclear supernatant by centrifugation at 16,000 x g for 40 min at 4 °C. The membranes were then resuspended in 25 µlof assay buffer (150 mM sodium citrate, pH 6.4, 1x Complete) and incubated at 37 °C for 4 h in the absence or presence of the indicated drugs. Samples were then analyzed by WB. |
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
levels. To this end, we treated APP695-transfected HEK293 cells with increasing concentrations of the different polyphenols and analyzed A levels by ELISA and WB. Total secreted A (Fig. 2, A and B, panel a), including secreted A40 (Fig. 2B, panel b) and A42 (Fig. 2B, panel c), were markedly reduced by 20–40 µM resveratrol after 24 h of incubation, whereas quercetin and catechin were apparently ineffective at these concentrations (Fig. 2, A and B, panel a). At the same concentration range, resveratrol also reduced total intracellular A (Fig. 2B, panel d). Because resveratrol treatment did not lead to intracellular accumulation of A (Fig. 2B, panel d), we concluded that A secretion was not impaired. To determine whether the effect of resveratrol is time-dependent, APP695-HEK293 cells were then treated for different periods of time with 10 or 20 µM polyphenol. Fig. 2C shows that, although resveratrol did not affect A levels after 12 h of incubation, its inhibitory effect on A levels is gradually strengthened after longer incubation periods of 48 and 72 h.
|
at the same concentration range in another cell line (Fig. 3A, panel a). Secreted A produced by N2a cells overexpressing APP695 bearing the familial AD Swedish mutation, was also reduced by similar treatments (Fig. 3B). To determine whether resveratrol affects APP metabolism, we then monitored by WB the levels of APP holoprotein and proteolytic fragments. At the same concentrations, resveratrol neither affected full-length APP levels (Fig. 2B, panel e, and Fig. 3A, panel e) nor reduced secreted APP immunoreactivity (Fig. 3A, panel f). In addition, resveratrol did not affect the steady-state levels of APP C-terminal fragments C99, C89, and C83 (Fig. 3A, panels b and c) and APP intracellular domain (AICD, Fig. 3A, panel d). Together these data indicate that resveratrol had no effect on the -, -, or -secretase-mediated cleavages of APP or on the stability of APP or its C-terminal fragments. Therefore, resveratrol did not affect APP metabolism and A production.
To confirm that resveratrol did not inhibit -or -secretase directly, resveratrol was used in a cell-free assay designed to produce A in vitro. In this in vitro assay, membrane preparations isolated from APP695-HEK293 cells were incubated at 37 °C for 4 h in the absence or presence of increasing concentrations of resveratrol. Production of A was not affected by the presence of resveratrol in vitro (Fig. 4a). However, the levels of A produced in vitro by membranes isolated from cells treated in culture with the polyphenol were significantly reduced (Fig. 4b), indicating that resveratrol promoted A reduction without directly affecting - and -secretases.
|
-Secretase targets several other type I proteins, including the cell-cell adhesion receptors E- and N-cadherins (15, 16). Cleavage of N-cadherin by -secretase produces the transcriptionally active intracellular fragment N-Cad/CTF2 from the proteolytic cleavage of the intermediate C-terminal fragment N-Cad/CTF1 (15). Using a similar cell-free assay we determined that production of N-Cad/CTF2 was not affected by resveratrol treatment (Fig. 4c), confirming the absence of inhibitory effect of resveratrol on -secretase activity. Together with the observation that resveratrol did not affect the levels of APP holoprotein and its C-terminal proteolytic fragments, these data indicate that resveratrol did not target an A-producing activity but rather promoted A clearance.
Based on these observations, we aimed to determine whether resveratrol treatment promotes A degradation. A peptides are degraded in vivo by at least four metalloendopeptidases, NEP, endothelin-converting enzyme-1 and -2 (ECE-1 and -2), and insulin-degrading enzyme (IDE) (17). Recent evidence indicates that long term treatment with resveratrol promotes NEP activity in SK-N-SH cells (18). Using thiorphan-sensitive enzymatic assays on intact HEK293 cells, we confirmed that NEP activity was significantly increased upon resveratrol treatment (Fig. 5A). However, inhibition of NEP with phosphoramidon or thiorphan in APP695-HEK293 cells could not prevent the decrease of A levels triggered by resveratrol (Fig. 5B). Because phosphoramidon also inhibits ECE-1 and -2, we concluded that these enzymatic activities were also not involved in the resveratrol-mediated decrease of A. Further, pretreatment with insulin, which acts as a competitive inhibitor of IDE, did not rescue A levels during resveratrol treatment (Fig. 5B). Thus, resveratrol did not promote A degradation by NEP, ECE-1 and -2, or IDE in HEK293 cells.
Converging evidence indicates that resveratrol promotes the proteasomal degradation of a specific subset of proteins, including cyclin D1 (19), the estrogen receptor- (20), or the hypoxia-inducible factor-1 (21). Because the proteasome has been shown to modulate A levels (22), we asked whether proteasome inhibition rescues A levels upon resveratrol treatment. Fig. 5B shows that treatments with the selective proteasome inhibitors, lactacystin, Z-GPFL-CHO, or YU101, significantly prevented the resveratrol-induced decrease of A. To confirm the involvement of the proteasome in the anti-amyloidogenic effect of resveratrol, we sought to down-regulate proteasome activity by siRNA-directed silencing. The proteasome is a multicatalytic protease complex formed by different subunits encoded by several genes (23). Because YU101 is highly selective for the chymotrypsin-like activity of the proteasome (24) and because the subunit 5 is critical for this proteolytic activity (23), we asked whether siRNA-directed silencing of the proteasome subunit 5 prevents the resveratrol-induced decrease of A. Transfection of siRNAs directed against the subunit 5 strongly decreased 5 protein expression (Fig. 5C, panel a) and inhibited more than 60% of the chymotrypsin-like activity of the proteasome (Fig. 5C). Under these conditions, we observed a strong inhibition of the resveratrol-induced A decrease (Fig. 5C, panel b).
|
levels after 24 h of incubation, we also asked whether resveratrol modifies proteasome subunit transcription. We found that resveratrol treatment does not markedly affect the steady-state levels of several proteasome subunits in HEK293 cells (Fig. 5C, panel a, and Fig. 5E, panel a). Together these results demonstrate that resveratrol promotes a proteasome-dependent intracellular degradation of A via a mechanism that does not increase total proteasome activity. Consistent with this conclusion, levels of -catenin, a cytosolic protein degraded by the ubiquitin proteasome system (25), are not affected by resveratrol in HEK293 cells (Fig. 5E, panel b).
We then investigated the anti-amyloidogenic effect of several resveratrol analogues. Three analogues were tested: piceatannol (trans-3,3',4,5'-tetrahydroxystilbene), which contains an additional hydroxyl group at C-3, and two methoxy analogues, trimethoxy-resveratrol (trans-3,4',5-trimethoxystilbene) and TMS. Interestingly, the three analogues were able to decrease A levels (Fig. 6). However, compared with resveratrol (Fig. 2A), piceatannol and trimethoxy-resveratrol were less potent, whereas TMS had a very comparable potency in reducing the amounts of A (Fig. 6).
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
produced by different cell lines expressing wild type or Swedish mutant APP695. Resveratrol acts by promoting the intracellular degradation of the amyloid peptide by a mechanism that implicates the proteasome. Pharmacological studies show that none of the previously reported A-degrading metalloendopeptidases, NEP, ECE-1 and -2, or IDE, are involved in this clearance. Finally, we demonstrate the anti-amyloidogenic activity of two methoxy analogues of resveratrol, trimethoxy-resveratrol and TMS, suggesting that chemical modifications of resveratrol can be done in the context of improving its potency, stability, and bioavailability and therefore its therapeutic use.
Additional studies will be needed to fully elucidate the role of the proteasome in this mechanism of intracellular clearance of A. A number of possible functions of the proteasome in the regulation of A metabolism have been ascribed to the multicatalytic complex (22). The proteasome targets for degradation C99 and three core components of the -secretase complex, presenilins, APH-1, and Pen-2 (22), suggesting that proteasome activation may decrease A levels by reducing the amounts of C99 available and by altering -secretase activity. Our data show no reduction of C99 levels (Fig. 3A, panel c) or alteration of the -secretase-mediated cleavages of APP or N-cadherin upon resveratrol treatment (Figs. 3 and 4), thus excluding the possibility that resveratrol lowers A by promoting the proteasomal degradation of C99 or any -secretase components. Recent evidence also suggests that A can be degraded by a proteasome-dependent endoplasmic reticulum (ER)-associated degradation (26). Using cell-free reconstitutions of ER-derived brain microsomes, Schmitz et al. (26) show that A can translocate from the ER to the cytosol where it is directly degraded by the proteasome. It is conceivable that resveratrol promotes such a clearance mechanism. However, because ER A represents a small fraction of total A produced and because a small pool of A produced in the ER appears to be controlled by ER-associated degradation, it is unlikely that the severe reduction of A levels observed in the presence of resveratrol is entirely due to an increase of this clearance mechanism. We therefore hypothesize that resveratrol may act indirectly by selectively stimulating the proteasomal degradation of yet to be identified critical regulators of A clearance.
It will be also important to determine what the molecular targets of resveratrol are in the pathway of A clearance. Resveratrol interacts with several proteins, including members of the sirtuin family. Sirtuins are evolutionarily conserved deacetylases with important functions in longevity (27). Resveratrol was found to act as a potent activator of the human sirtuin SIRT1 in vitro and of the yeast homologue Sir2 in vivo, a mechanism that may extend life span in yeast (28). Moreover, resveratrol and SIRT1 activation have recently been linked to neuroprotective pathways in models of axonal degeneration (29) and of neuronal dysfunctions caused by mutant polyglutamines (30). It would therefore be of interest to determine whether SIRT1 is involved in the resveratrol-induced decrease of A.
Evidence is compelling that a decrease in proteasome activity occurs in AD brains (31, 32). It is unclear, however, whether this decrease in proteasome activity is in parallel with an increase in A levels. It has been proposed that A itself may lead to proteasome inhibition (33), suggesting that high levels of A in AD brain may create a vicious cycle by inhibiting the proteasome and blocking the degradation of critical regulators of its own clearance. In this context, our data reveal an important mechanism of selective proteasome activation in the anti-amyloidogenic effect of resveratrol and support the therapeutic potential of this natural polyphenol.
|
FOOTNOTES |
|---|
1 To whom correspondence should be addressed: The Litwin-Zucker Research Center for the Study of Alzheimer's Disease and Memory Disorders, North Shore-Long Island Jewish Institute for Medical Research, 350 Community Dr., Manhasset, NY 11030. Tel.: 516-562-3492; E-mail: pmaramba{at}aecom.yu.edu.
2 The abbreviations used are: AD, Alzheimer's disease; Suc, succinyl; TMS, trans-2,3',4,5'-tetramethoxystilbene; ALLN, N-acetyl-LL-norleucinal-CHO; ELISA, enzyme-linked immunosorbent assay; ECE, endothelin-converting enzyme; IDE, insulin-degrading enzyme; A, amyloid-; APP, amyloid- precursor protein; AMC, amido-4-methylcoumarin; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; WB, Western blotting; IP, immunoprecipitation; NEP, neprilysin; MOPS, 4-morpholinepropanesulfonic acid; ER, endoplasmic reticulum; siRNA, small interfering RNA; TBS, Tris-buffered saline; sA, secreted amyloid-; Z, benzyloxycarbonyl.
|
ACKNOWLEDGMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Onozuka, A. Nakajima, K. Matsuzaki, R.-W. Shin, K. Ogino, D. Saigusa, N. Tetsu, A. Yokosuka, Y. Sashida, Y. Mimaki, et al. Nobiletin, a Citrus Flavonoid, Improves Memory Impairment and A{beta} Pathology in a Transgenic Mouse Model of Alzheimer's Disease J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 739 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Catoire, M. Y. Pasco, A. Abu-Baker, S. Holbert, C. Tourette, B. Brais, G. A. Rouleau, J. A. Parker, and C. Neri Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1 Hum. Mol. Genet., July 15, 2008; 17(14): 2108 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bacher, R. Dodel, B. Aljabari, K. Keyvani, P. Marambaud, R. Kayed, C. Glabe, N. Goertz, A. Hoppmann, N. Sachser, et al. CNI-1493 inhibits A{beta} production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease J. Exp. Med., July 7, 2008; 205(7): 1593 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, L. Ho, W. Zhao, K. Ono, C. Rosensweig, L. Chen, N. Humala, D. B. Teplow, and G. M. Pasinetti Grape-Derived Polyphenolics Prevent A{beta} Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer's Disease J. Neurosci., June 18, 2008; 28(25): 6388 - 6392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, L. Ho, Z. Zhao, I. Seror, N. Humala, D. L. Dickstein, M. Thiyagarajan, S. S. Percival, S. T. Talcott, and G. M. Pasinetti Moderate consumption of Cabernet Sauvignon attenuates A{beta} neuropathology in a mouse model of Alzheimer's disease FASEB J, November 1, 2006; 20(13): 2313 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Masters and K. Beyreuther Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway Brain, November 1, 2006; 129(11): 2823 - 2839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Weissmann Dietary supplements: red wine, ortolans, and chondroitin sulfate FASEB J, May 1, 2006; 20(7): 803 - 805. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
